Personalization is improving consumer experiences everywhere, but in medicine, it has the potential to improve outcomes. We know that each person is different — not only in terms of their medical history, but also their personality, motivations, and values — and those differences can be amplified when it comes to making decisions about their health.

Increasingly enabled by emerging technologies such as AI, innovations in this space are reshaping the therapeutic landscape and making way for the proactive management of disease. Ultimately, technology could be used to prevent people from becoming patients in the first place.

New solutions have to be frictionless, but more importantly, they have to meet the changing appetites of customers driven largely by personalization. During this session, panelists will share their insights on the opportunities and challenges associated with personalization in the life sciences field, highlighting how technology can drive personalization and insights that benefit patients, healthcare providers, and the industry as a whole.

In today’s environment, patient’s aren’t simply patients, they’re consumers. As such, consumers expect an immediate response delivery model in all aspects of their life, be it shopping (ex: Amazon), entertainment (ex: Disney Plus, Hulu, Netflix) or even ordering groceries (ex: grocery home delivery). Why can’t consumers expect a similar experience with their healthcare and why can’t manufacturer- sponsored programs deliver this same experience? The fact is they can, if they partner with the right organizations that focus on providing the services that meet these expectations. A July 2021 survey from Phreesia Life Sciences found that Pharmaceutical manufacturers spend more than $5B annually on patient support programs but only 3% of patients actually use these programs – we can do better.

In addition, manufacturers are currently faced with all new challenges including service providers that are challenged with ongoing staffing issues and many times burdened by legacy systems. Manufacturers effectively have service providers that are not being able to find enough personnel to support the services required while being hamstrung by systems with limited flexibility.

D2’s modularized solutions have been developed in conjunction with actual users to capture and maintain patient interaction with tools that a) digitally engage patients via a customized gaming technology approach saving manhours, and frustration for patient’s, providers and staff and b) accelerate the Approval of Prior Authorizations (from weeks to hours or minutes).

Learn more about how technology solutions can help capture more patients and keep them on therapy longer.

A full 99% of life sciences organizations consider digital transformation to be a worthy endeavor, but just 12% are fully digital, according to new Salesforce research. With the rapid advancements in blockchain technology, data analytics, and artificial intelligence, companies in the life sciences sector are now looking to leverage these digital technologies to optimize their operations, enhance patient outcomes, and accelerate drug discovery and development (Gyan Consulting).

A scattershot approach to digital will no longer work for those who want to succeed in driving business value and delivering customer- and patient-centric experiences. Biopharma and MedTech companies are expected to evolve from just doing digital—to being digital.

For life sciences organizations to stay competitive in the digital healthcare industry, it's crucial that they move away from adopting digital technologies in isolated areas, and instead undertake comprehensive enterprise-wide digital transformation initiatives. Failure to do so may result in these companies being marginalized or constrained within the future digital healthcare ecosystem. (Gyan Consulting)

Questions to answer in this roundtable include:

• What is the difference between digital optimization and digital transformation in life sciences?
• Is modernizing processes/systems across the entire value chain and in core functions enough?
• What are the key challenges and risks in scaling up emerging technology in the life sciences industry when considering regulation, privacy and patient protection?
• With the life sciences industry being so heavily regulated, what can companies do to stay compliant while also working to modernize and digitize?
• With a multitude of systems and platforms being utilized across the industry, how can organizations work to improve interoperability so that data can easily be shared and exchanged between stakeholders?
• What can organizations do to modernize their legacy systems?

Life sciences is primed for an innovation explosion, and AI and ML will be key to accelerating it. From research and development to clinical trials, along with health care delivery and patient care, cutting-edge technologies like artificial intelligence and machine learning are adding enormous value across the life sciences value chain.

And we may just be at the edge of the innovation boom. According to figures from Deloitte, about 80% of MedTech executives said the development of innovative products was a “top priority” for 2023; and 75% intend to focus more on their R&D investments. No surprise then, that Gartner says 51% of life sciences companies are increasing investments in AI/ML, to fuel all that innovation. According to Precedence Research, the global AI in life sciences market size is projected to worth around US$ 6.7 billion by 2030 and growing at a CAGR of 20% from 2022 to 2030.

Applying AI to big data in life sciences can help companies reshape business models and also enable life sciences companies to be more personalized and authentic in how they engage with health care professionals, patients, and other stakeholders. (Deloitte). The life sciences industry has likely only scratched the surface of the potential for technology to shape its future for the better, and AI and ML will no doubt continue to have a seat at the table.

Questions to answer in this roundtable include:

• What specific applications of AI and ML have the most potential to revolutionize the life sciences industry?
• How can AI/ ML be used to improve drug discovery and development processes? What about personalizing medicine and improving patient outcomes?
• How are you navigating the regulatory and compliance issues that come with the use of AI in the life sciences industry?
• How can organizations address the ethical concerns that come with the use of AI/ML?
• How can the life sciences industry gain the approval and trust of its stakeholders over the use of these technologies?

Superior patient experience boosts the reputation of life sciences organizations among patients, positively influences clinical outcomes, and has an indirect yet critical impact on life sciences’ bottom line. However, delivering a superior patient experience is anything but easy – it requires significant monetary and time investments, a patient-centric mindset, seamless coordination with care delivery teams, and the right digital means to enrich patient lives wherever possible (Indigene).

Additionally, IDC analysts predict that by 2025, 60% of life science firms will use health data platforms for physician engagement, along with patient journey processes. The connection of quality information that can be securely exchanged will support the patient and provider experience, and enable the growing demand for telemedicine and remote care.

Questions to answer in this roundtable discussion include:

• Digital is a key theme in improving the patient journey. But how do you balance the human and technology element to deliver better patient engagement and outcomes?
• How can we adapt and change technology as we learn more about patient need?
• What are some of the challenges that life sciences companies face when attempting to implement patient-centric processes, and how can these challenges be addressed?
• How does patient activation support better outcomes?
• How can life sciences organizations ensure they are providing meaningful digital assets?
• How can life sciences organizations ensure the patient voice is considered in the creation of products, decisions, and directions?
• How can patient feedback be effectively incorporated into the development of patient journey processes in life sciences?
• What is the future of patient engagement and journey processes in life sciences, and how can companies stay ahead of the curve in this rapidly evolving field?

Since childhood, Dr. Tolentino has helped innovate effective treatments for blinding conditions using the strategy of simplification. His presentation will recount how simplification helped his father develop retinal detachment surgery, allowed him to innovate eye injections for wet macular degeneration/diabetic retinopathy and facilitated his invention of a potentially vision restoring treatment for dry macular degeneration. He will conclude by simplifying how to cure cancer.

GenAI has taken the world by storm and we're all riding the wave. While our journey at Whitespace hasn't had the headline-grabbing drama of recent events at OpenAI, our experience working with Health and Life Sciences companies underscores the importance of balancing the hype with the human side of things. In this session, we will share our thoughts on AI from the perspectives of employees, patients, and clinicians, as well as how we see the technology landscape evolving to support greater Human-AI collaboration, risk mitigation, and trust.